Abstract: Valemetostat (DS-3201, EZHARMIA) is a novel, orally bioavailable, and selective dual inhibitor of the enhancer of zeste homolog 1 and 2 (EZH1/2) enzymes, which are core catalytic subunits of the polycomb repressive complex 2 (PRC2). By inhibiting both EZH1 and EZH2, valemetostat effectively suppresses the tri-methylation of histone H3 at lysine 27 (H3K27me3), thereby reversing the epigenetic silencing of tumor suppressor genes implicated in various malignancies. Valemetostat received its first global approval in Japan in September 2022 for the treatment of relapsed or refractory adult T-cell leukaemia/lymphoma (R/R ATL). It has demonstrated significant clinical efficacy in R/R ATL and peripheral T-cell lymphoma (PTCL), exhibiting manageable safety profiles, though adverse events such as thrombocytopenia and alopecia require monitoring. This review synthesizes current literature on valemetostat, detailing its pharmacological activity, molecular mechanism, structure-activity relationships, clinical limitations, and future therapeutic perspectives in T-cell lymphomas and beyond.
1. Introduction
Epigenetic regulators of gene expression represent a critical and emerging class of targets for cancer therapy. The polycomb repressive complex 2 (PRC2) is a key epigenetic regulator that catalyzes the mono-, di-, and tri-methylation of the 27th lysine residue of histone H3 (H3K27), leading to chromatin compaction and the repression of genes associated with tumor suppression and cell differentiation [1][2]. Enhancer of zeste homolog 1 (EZH1) and 2 (EZH2) serve as the alternative catalytic subunits of PRC2. Gain-of-function mutations or the overexpression of EZH2 lead to inappropriate H3K27me3 deposition, which drives the abnormal transcriptome implicated in the development and progression of various hematological malignancies, including non-Hodgkin lymphomas (NHL) [1].
Among NHL subtypes, T-cell lymphomas such as adult T-cell leukaemia/lymphoma (ATL)—which arises from T cells infected with human T-lymphotropic virus type 1 (HTLV-1)—and peripheral T-cell lymphoma (PTCL) are rare, aggressive, and notoriously difficult to treat. Standard multiagent chemotherapy often fails to provide durable responses, leading to poor prognoses for relapsed or refractory (R/R) patients [1]. Valemetostat tosilate (valemetostat; EZHARMIA) was developed by Daiichi Sankyo as a first-in-class, orally administered, selective dual inhibitor of both wild-type and mutated forms of EZH1 and EZH2 [1][2]. Based on promising clinical trial results, valemetostat received its first regulatory approval in Japan on September 26, 2022, for the treatment of patients with R/R ATL [1].
2. Pharmacological Activity
Valemetostat exhibits potent antiproliferative activity across various hematological cancer cell lines. In vitro, it has demonstrated significant efficacy against the TL-Om1 cell line (derived from human ATL) and various subtypes of diffuse large B-cell lymphoma (DLBCL), inducing cell differentiation, growth inhibition, and apoptosis regardless of EZH2 mutation status [1][2]. In preclinical in vivo models, oral administration of valemetostat reduced tumor growth in ATL and DLBCL xenografts, achieving almost complete tumor regression at optimal doses without significant weight loss [1].
Clinically, valemetostat has shown promising efficacy in patients with R/R ATL and PTCL. In a pivotal Japanese phase 2 trial (NCT04102150) involving patients with R/R ATL receiving 200 mg once daily, the overall response rate (ORR) was 48%, with a complete response (CR) rate of 20% and a partial response (PR) rate of 28%. The tumor control rate was 88.0% [1]. In a phase 1 trial (NCT02732275) dose expansion cohort, the ORR in the R/R PTCL subset was 54.5%, with CR and PR both at 27.3% [1].
Pharmacokinetically, valemetostat is highly protein-bound (94-95%) and is predominantly metabolized by the CYP3A enzyme. Following a single oral 200 mg dose in the fasted state, the steady-state mean maximum concentration (Cmax) is achieved in a median of 3.79 hours. The drug is mainly excreted in feces (79.8% of total radioactivity) and has a mean elimination half-life of 11.1 hours [1].
3. Molecular Mechanism of Action
Valemetostat functions by inhibiting the methylation activity of both EZH1 and EZH2. In cell-free enzymatic assays, it demonstrates an IC50 of 10.0 nM for EZH1 and 6.0 nM for EZH2 [1]. By inhibiting these enzymes, valemetostat suppresses the tri-methylation of the lysine residue at position 27 of histone H3 (H3K27me3). This decrease in histone methylation alters cancer-associated gene expression patterns, reactivates epigenetically silenced tumor suppressor genes, and ultimately decreases the proliferation of EZH1/2-expressing cancer cells [1].
A critical mechanistic advantage of valemetostat over selective EZH2 inhibitors (such as tazemetostat) is its dual inhibition profile. Preclinical studies have shown that when cells are exposed to selective EZH2 inhibition, EZH1 can compensate for the loss of EZH2, leading to ectopic EZH1/2 accumulation at tumor suppressor gene loci and only a partial reduction in H3K27me3. In contrast, valemetostat treatment is not associated with ectopic enrichment of EZH1/2, ensuring that H3K27me3 levels remain thoroughly depleted and silenced gene expression is effectively reversed [1][2].
4. Structure-Activity Relationship (SAR)
The chemical name for valemetostat tosilate is (2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide mono(4-methylbenzenesulfonate) [1]. Valemetostat acts as an S-adenosylmethionine (SAM)-competitive inhibitor of both EZH1 and EZH2 [2]. The structural design allows it to bind effectively to the SAM binding pocket of the PRC2 catalytic subunits, preventing the transfer of methyl groups to the histone substrate. Its dual affinity for both EZH1 and EZH2 provides a significant structural and functional advantage, granting it greater efficacy against potential drug resistance mechanisms that typically arise when only EZH2 is targeted [2].
5. Current Limitations
Despite its clinical efficacy, valemetostat therapy is associated with several limitations and safety concerns. The most frequent adverse reactions include thrombocytopenia, anaemia, alopecia, dysgeusia, lymphopenia, neutropenia, and leukopenia [1][2]. Thrombocytopenia is a notable adverse event of special interest; in clinical trials, severe (grade 4) thrombocytopenia required dose modifications, interruptions, or treatment discontinuation [1]. Patients require careful monitoring for myelosuppression during treatment.
Valemetostat is also subject to significant pharmacokinetic interactions. Food has a profound effect on its absorption; high-fat and low-fat meals significantly reduce the Cmax and AUC of the drug, necessitating administration strictly in a fasted state (avoiding food 1 hour before and 2 hours after dosing) [1]. Furthermore, because it is metabolized by CYP3A and is a substrate/inhibitor of P-glycoprotein (P-gp), coadministration with strong CYP3A or P-gp inhibitors (e.g., itraconazole) significantly increases valemetostat exposure, requiring dose reductions. Conversely, CYP3A inducers (e.g., rifampicin) decrease its exposure [1]. Finally, secondary malignancies, such as chronic myelomonocytic leukaemia, have been reported in clinical studies, highlighting the need for long-term safety monitoring [1].
6. Future Perspectives
The clinical development of valemetostat is rapidly expanding beyond its initial approval for R/R ATL. Numerous ongoing clinical trials are investigating its efficacy in other hematological malignancies and solid tumors. For instance, the global phase 2 VALENTINE trial (NCT04703192) is evaluating valemetostat in a larger cohort of patients with R/R PTCL, while the VALYM trial (NCT04842877) is assessing its use in R/R B-cell lymphomas [1][2].
In addition to monotherapy, valemetostat is being explored in combination regimens to overcome resistance and enhance therapeutic efficacy. Ongoing trials are testing it in conjunction with agents such as rituximab, lenalidomide, atezolizumab, and ipilimumab across various indications, including metastatic prostate, urothelial, and renal cell cancers, as well as recurrent small cell lung cancer [1][2]. Furthermore, pediatric trials (e.g., the ELEPHANT trial) are investigating its safety and efficacy in children and young adults with malignant solid tumors [1]. As research progresses, identifying predictive biomarkers for PRC2 inhibitor responsiveness will be crucial for patient stratification and optimizing the clinical utility of valemetostat [2].
